Skip to content
Triangle logo TriangleGet started
← Study library

NCT00507767 · REGISTRY CONDITION SEARCH

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2014-10-01

This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome

Number of Participants With Progression-free Survival at 12-weeks

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patient has histologically proven squamous cell carcinoma of the head and neck that is recurrent after surgery and/or radiation therapy or chemoradiation therapy or is metastatic and disease must be measurable by RECIST criteria * Patients must have measurable disease as defined by RECIST criteria * Patients have received =\< 1 prior chemotherapeutic regimen for recurrent or metastatic disease * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Hemoglobin (Hgb) \>= 9.0 g/dL * Total bilirubin =\< 1.5 X upper limit of normal * Albumin \>= 2.5 g/dL * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =\< 1.5 X upper limit of normal * Creatinine =\< 3 mg/dl * Paraffin embedded tumor tissue that is appropriate for immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) analysis must be available or patient must be amenable to biopsy to obtain tissue for the study * Ability to understand and the willingness to sign a written informed consent document * Patient must not be pregnant or breastfeeding; all sexually active females of child-bearing potential and all sexually active males with sexual partners of child-bearing potential should practice contraception (e.g. barrier, hormonal, intrauterine device \[IUD\]) or sexual abstinence while in the study and for two months following completion of therapy * Brain metastases permitted provided the patient does not require anticonvulsants or corticosteroids, or has been off them at least 7 days; patients with brain metastases must be either \> 4 weeks beyond cranial irradiation or must be felt not to require it at that time * The patient's O2 saturation must be \>= 92% on room air Exclusion Criteria: * Chemotherapy or palliative radiotherapy for recurrent and/or metastatic disease within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or failure to recover to at least grade 1 from adverse events due to agents administered more than 4 weeks earlier; concomitant chemoradiation therapy within 6 weeks prior to entering the study or failure to recover to at least grade 1 from adverse events due to agents administered more than 4 weeks earlier * Other anti-neoplastic agents, i.e., cytotoxic chemotherapy, immunotherapy, radiotherapy or investigational therapy, used to treat the primary disease will not be allowed during the study; local radiation (excluding radiotherapy to the target lesion) for supportive reasons involving a small radiation field may be allowed * Patient has a history of uncontrolled or severe medical disease which could compromise participation in the study such as uncontrolled diabetes (fasting blood glucose \> 200 mg/dl), uncontrolled hypertension (systolic blood pressure \[BP\] \> 160 or diastolic BP \> 100 mmHg), severe infection (bacterial infection requiring intravenous \[IV\] antibiotics or human immunodeficiency virus \[HIV\]), angina at rest, congestive heart failure New York Heart Association (NYHA) class III or IV, ventricular arrhythmias requiring therapy, myocardial infarction within 6 months, \> grade 2 neuropathy * Patients may not be receiving any other investigational agents * Patients who require concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; efforts should be made to switch patients with gliomas or brain metastases who are taking enzyme-inducing anticonvulsant agents to other medications * Echocardiogram less than institutional normal measured by echocardiogram for subjects with history of congestive heart failure, symptoms of congestive heart failure, clinical evidence suggesting impaired cardiac function * Patients may not have any clinically significant cardiovascular disease including the following: * Myocardial infarction or ventricular tachyarrhythmia within 6 months * Prolonged correct QT interval (QTc) \> 480 msec (Fridericia correction) * Major conduction abnormality (unless a cardiac pacemaker is present) * Pregnant women and women who are currently breast-feeding may not participate in this study; all women of childbearing potential must have a negative pregnancy test within 72 hours prior to enrolling in the study; postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential * Patients having pleural effusion
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: dasatinib
    2. Procedure: pharmacological study
    3. Procedure: laboratory biomarker analysis
    label
    Treatment (dasatinib)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (dasatinib)
    description
    Given PO or via PEG tube
    name
    dasatinib
    other Names
    1. BMS-354825
    2. Sprycel
    type
    DRUG
  2. arm Group Labels
    1. Treatment (dasatinib)
    description
    Correlative studies
    name
    pharmacological study
    other Names
    1. pharmacological studies
    type
    PROCEDURE
  3. arm Group Labels
    1. Treatment (dasatinib)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    PROCEDURE
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
15
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.
    measure
    Number of Participants With Progression-free Survival at 12-weeks
    time Frame
    At 12-weeks
Full study description
brief Summary
This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
detailed Description
PRIMARY OBJECTIVES: I. To determine the 12-week progression-free survival rate and the objective response rate, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with dasatinib. SECONDARY OBJECTIVES: I. To define metabolic response rate by positron emission tomography (PET) scan at 0, 8, and 12 weeks. II. To define overall survival distribution from initiation of dasatinib. III. To define duration of response. IV. To determine if there is a correlation between clinical benefit from dasatinib (defined as disease response or stabilization) and pharmacokinetics, pharmacodynamics (phosphorylated Src \[pSrc\] expression in platelets), or changes in serum levels of cytokines, growth factors, and growth factor receptors relevant to the Src signaling pathway. V. To examine the relationship between clinical benefit and mammary tumor and squamous cell carcinoma-associated protein (EMS1) gene amplification and cortactin expression levels in tumor tissue prior to therapy and the modulation of cortactin levels by treatment. VI. To compare the effects of dasatinib on apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay in tumor tissues comparing pre- and post-treatment biopsies. VII. To assess the tolerability of dasatinib in this patient population. VIII. To describe the pharmacokinetic (PK) profile and relative bioavailability of dasatinib suspension in patients receiving the drug through percutaneous gastrostomy tube. IX. To descriptively assess safety, toxicity, and efficacy of dasatinib crushed and administered by feeding tube. OUTLINE: Patients receive dasatinib orally (PO) or via percutaneous gastrostomy (PEG) tube twice daily (BID). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for at least 4 weeks.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3decedaf72b99d529934
      requested nct id
      NCT00507767
      primary nct id
      NCT00507767
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      4feb5517d960a8e9f78e16f79fc55fdadc11aaefc4659c3589f72301206a90f1
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3decedaf72b99d529934
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00507767
      occurrences
      1. context exact
        NCT00507767
        end
        11
        exact text
        NCT00507767
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/77/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1750789d7a512ad126642dd3f55d493a6d544646be2a0c114b3c138fa6108d44
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6cf9ea814b4a1560906a
      requested nct id
      NCT00507767
      primary nct id
      NCT00507767
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      payload sha256
      6944f206a9bc47a7c4dd62c35cf5689c77af8726d4192a1a685e467887ae59ef
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6cf9ea814b4a1560906a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00507767
      occurrences
      1. context exact
        NCT00507767
        end
        11
        exact text
        NCT00507767
        start
        0
      offset unit
      unicode_code_points
      query cond
      Salivary Gland Cancer
      query disease state id
      ds-salivary-gland-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      source json pointer
      /studies/42/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1750789d7a512ad126642dd3f55d493a6d544646be2a0c114b3c138fa6108d44
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6e51717b1ab5e43964a6
      requested nct id
      NCT00507767
      primary nct id
      NCT00507767
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      f033c4b095724e75f904f8e612bdfe750381acc37c420efbf966ec82f81ce13c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6e51717b1ab5e43964a6
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00507767
      occurrences
      1. context exact
        NCT00507767
        end
        11
        exact text
        NCT00507767
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/102/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1750789d7a512ad126642dd3f55d493a6d544646be2a0c114b3c138fa6108d44
    4. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-ab1d311251ae39699c51
      requested nct id
      NCT00507767
      primary nct id
      NCT00507767
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
      payload sha256
      d506b1e284f16f7cbe311c538f394e8b052cd36a28bee73a1cc6a73be07987f9
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-ab1d311251ae39699c51
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00507767
      occurrences
      1. context exact
        NCT00507767
        end
        11
        exact text
        NCT00507767
        start
        0
      offset unit
      unicode_code_points
      query cond
      Metastatic Squamous Neck Cancer With Occult Primary
      query disease state id
      ds-metastatic-squamous-neck-cancer-with-occult-primary
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-metastatic-squamous-neck-cancer-with-occult-primary-000.json
      source file sha256
      2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
      source json pointer
      /studies/22/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1750789d7a512ad126642dd3f55d493a6d544646be2a0c114b3c138fa6108d44

    Preserved source evidence · Not medical advice